Objectives. Our purpose was to evaluate the relation between smoking and the outcomes of patients receiving thrombolysis for acute myocardial infarction.
Results. Smokers were significantly younger by a mean of 11 years) and had less comorbidity or severe coronary artery disease than nonsmokers. Nonsmokers had significantly higher hospital and 30-day mortality rates (9.9% and 10.3%, respectively) than smokers (3.7% vs. 4%, respectively, both p < 0.001) and more in-hospital complications. The unadjusted odds ratio for 30-day mortality in nonsmokers was 3.36 (95% confidence interval [CI] 2.08 to 5.41), 1.21 (95% CI 0.71 to 2.08) after adjustment for age and gender and 1.08 (95% CI 0.59 to 1.96) after adjustment for all clinical baseline characteristics.
Conclusions. Smokers receiving thrombolysis for acute myocardial infarction presented 11 years earlier than nonsmokers, which generally accounted for their better outcome. When other differences in clinical and angiographic baseline factors and therapeutic responses were evaluated, no significant difference in mortality was seen between smokers and nonsmokers.
(J Am Coil Cardiol 1995; 26:1222-9) Despite many epidemiologic studies (1) (2) (3) (4) showing that cigarette smoking is associated with higher rates of myocardial infarction and death from coronary artery disease, several large clinical trials have demonstrated that smokers who have an acute myocardial infarction have a better prognosis than nonsmokers (5) (6) (7) . It has been proposed (7) that this paradox occurs because smokers who present with myocardial infarction differ as to extent of coronary vessel disease and have lesions that are more thrombogenic than atherogenic. Although the population of patients with myocardial infarction treated with thrombolytic therapy is relatively low risk, it provides an ideal cohort to study the epidemiology of risk factors. The first Global Utilization of Streptokinase and TissuePlasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial (8) , with its angiographic substudy (9) , pro-vided an opportunity to explore this paradox by correlating clinical outcomes with baseline clinical characteristics and the extent and nature of coronary artery disease in a large number of smoking and nonsmoking patients with acute myocardial infarction. We report the results of an analysis of the effects of smoking in the GUSTO-I population.
Methods
Patient population. Thrombolytic therapy. Overall, 41,021 patients with acute evolving myocardial infarction were randomized to receive one of four intravenous thrombolytic strategies according to the GUSTO-I protocol: 1) 1.5 million U of streptokinase over 60 min with subcutaneous heparin (12,500 IU) twice daily beginning 4 h after initiation of thrombolytic therapy; 2) 1.5 million U of streptokinase over 60 min with an intravenous heparin bolus of 5,000 U, then 1,000 U/h, adjusted to maintain an activated partial thromboplastin time of 60 to 85 s; 3) accelerated recombinant tissuetype plasminogen activator (rt-PA) (15-mg bolus), then 0.75 mg/kg body weight over 30 min (not to exceed 50 mg), then 0.5 mg/kg (up to 35 mg) over the next 60 min with the same intravenous heparin regimen; or 4) the combination of intravenous rt-PA (1.0 mg/kg over 60 rain, not to exceed 90 mg, with 10% given as a bolus) and streptokinase (1.0 million U over 60 min) given simultaneously, followed by the same intravenous heparin regimen. The study design, inclusion and exclusion criteria, trial medications and guidelines for patient management have been described in detail elsewhere (8) .
Smoking status (current smoker, nonsmoker, ex-smoker) was obtained from the patient or a representative at the time of randomization, as was the average number of cigarettes smoked each day. Information on the duration of nonsmoking (for ex-smokers) was not available for analysis. Smoking status was not assessed during hospitalization or after discharge.
The clinical outcomes analyzed were hospital and 30-day mortality, in-hospital reinfarction, cardiogenic shock, congestive heart failure, major arrhythmias, stroke, hemorrhage, and worst Killip class during the hospital stay. The baseline characteristics analyzed were age (->70 and 60 to 69 vs. <60 years), gender, weight, infarction site, diabetes mellitus, previous infarction, antecedent angina, hypertension, smoking status, family history of cardiovascular disease, hypercholesterolemia, Killip class at entry (>I vs. I) and time from onset of symptoms to treatment initiation (>3 vs. -<3 h).
Angiographie studies. In the angiographic substudy (9), 2,431 GUSTO-I patients were also randomly assigned to undergo cardiac catheterization at one of four times after the initiation of thrombolytic therapy: 90 rain, 180 min, 24 h or 5 to 7 days. Patients who had a 90-rain study also had a 5-to 7-day follow-up angiogram. The principal end points for the angiographic substudy were infarct-related artery patency, reocclusion and left ventricular function. The angiographic study protocol and methods of analysis have been described in detail elsewhere (9) . The films were analyzed in blinded manner with regard to treatment assignment or clinical data. Both coronary. and ventriculographic analyses were performed using reproducible, quantitative techniques.
Statistical methods. Baseline characteristics and clinical outcomes were tested by means of a chi-square test for trend for discrete variables and by analysis of variance for continuous variables. Angiographic characteristics (anatomy, extent of disease and left ventricular dysfunction) were compared for nonsmokers versus current smokers and for nonsmokers versus current and ex-smokers combined. This was done under the prospective assumption that the ex-smokers would have risk factors and outcomes of intermediate severity compared with nonsmokers and current smokers but that would be closer to those of the current smokers. Nominal p values are reported for each comparison, although caution must be exercised in the interpretation of these values. This study represents an ancillary analysis of a large data base with multiple purposes; accordingly, the statistical comparisons reported herein represent a fraction of the total comparisons performed on the data base. The issue of multiplicity must be considered because some of these comparisons would be expected to be nominally "statistically significant" by chance. In addition, given the large sample size of this study, a "significant" comparison must be scrutinized for clinical relevance because small, clinically unimportant differences can have small p values.
To maximize the explanatory function of the statistical models to predict outcomes and to avoid repeating modeling processes already completed on the GUSTO-I data base, we proceeded by means of a prespecified modeling strategy.
1. The entire GUSTO-I clinical data base was used to examine the relation between smoking and mortality after adjusting for other features of the patients. Initially, the effects of smoking were evaluated using logistic regression analysis after adjusting for only age and gender. A previously developed (10) detailed mortality model was then used to evaluate the simultaneous impact of multiple baseline characteristics on the prognostic importance of smoking. This model includes the following additional prognostic variables: systolic blood pressure; Killip class; heart rate; location of infarction; previous myocardial infarction; previous bypass surgery; height; time to thrombolytic therapy; type of thrombolytic therapy; weight; and previous diabetes, hypertension or cerebrovascular disease.
2. The smaller (2,431 patients) angiographic substudy (9) data base was then interrogated, first adjusting for only age and gender, then adjusting again for the entire clinical model. Because the power to detect significant differences was markedly lower in the angiographic substudy data base, we were most interested in the magnitude of the estimated effect rather than its statistical significance.
3. The angiographic factors of left ventricular ejection fraction, Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow, and the number and extent of lesions were included in the model. In each case, the effect of smoking was characterized after adjusting for all prognostic factors thought to be important.
Odds ratios and 95% confidence intervals for 30-day mor- tality were calculated using standard methods. Odds ratios computed from the logistic coefficients are presented, followed by 95% confidence limits computed on the basis of the standard error of the coefficients. Categoric variables are presented as number and percent of patients with the characteristic; continuous variables are given as mean value _+ SD.
Results
Study population. Of the 41,021 patients randomized, smoking status was not defined in 380 patients (0.9%) and baseline data on an additional 42 patients (0.1%) were missing. Thus, 40,599 patients were included in the present analysis (11,975 nonsmokers, 11,117 ex-smokers and 17,507 current smokers). The baseline characteristics of the three groups differed significantly (Table 1) . Nonsmokers had consistently worse baseline characteristics than current smokers: they were older and had a higher rate of hypertension, diabetes mellitus, anterior wall infarction and Killip class >I at admission. With the exceptions of angina and previous myocardial infarction, the rates in ex-smokers were intermediate between current smokers and nonsmokers. Smokers were treated an average of 10 min earlier than nonsmokers. All of these differences were highly significant.
Angiographic findings: evidence of different pathogenesis. A total of 2,431 patients were enrolled in the angiographic substudy and underwent coronary angiography during the index hospital stay. Current smokers had a significantly higher rate of single-vessel coronary artery disease (Table 2) . Current smokers had more right coronary artery occlusion (49%) than ex-smokers (47%) or nonsmokers (38%, p < 0.0001). There was a significant difference in 90-rain perfusion; 41% of current and ex-smokers had TIMI grade 3 flow in the infarct-related artery compared with only 33% of nonsmokers (p = 0.02). At 90-min coronary angiography, intracoronary thrombus was documented in a similar percent of each patient group.
There was no difference among the three groups in minimal lumen diameter or percent stenosis nor in the amount of change for these variables from initial to follow-up angiography (Table 3) . A significantly lower rate of in-hospital reocclusion was observed in smokers than in nonsmokers and exsmokers (2.7% vs. 7.7% and 9.8%, respectively, p < 0.01). 12ft ventricular function. Table 4 summarizes the analysis of left ventricular function relative to smoking status. Current smokers had the highest left ventricular ejection fraction, with the ex-smokers as an intermediate group. Compared with nonsmokers, current and ex-smokers had significantly less depression of regional wall motion in the ischemic zone, as expressed by the smaller number of abnormal chords.
In.hospital clinical outcomes. Table 5 presents in-hospital clinical outcomes. Nonsmoking patients had the worst inhospital outcomes, smokers the best, with ex-smokers constituting an intermediate group. Specifically, the nonsmoking patients had higher rates of reinfarction; congestive heart failure; or pulmonary edema, shock, strokes (including primary hemorrhagic and nonhemorrhagic strokes), moderate-tosevere bleeding and more severe Killip class. These differences were all statistically significant. 644 (5) 523 (5) 612 (4) < 0.001 IV 726 (6) 493 (4) 579 (3) *Chi-square test for trend, unless otherwise indicated, comparing current smokers, ex-smokers and nonsmokers as three groups, tChi-square test. Data presented are number (%) of patients. AV = atrioventricular; CHF = congestive heart failure.
Mortality.
In-hospital and 30-day mortality rates were higher for nonsmokers than for ex-or current smokers (p < 0.001) (Fig. 1, Table 5 ). Discharge to 30-day mortality was also higher in nonsmokers and ex-smokers than in smokers (0.4% for nonsmokers and ex-smokers vs. 0.3% for smokers, p < 0.001). Both in-hospital and 30-day mortality significantly decreased in smokers as the number of cigarettes smoked each day increased (p < 0.001) (Fig. 2, top) . This pattern was Non-Smoking maintained after adjustment for age and gender, although mortality did increase somewhat in the heaviest smokers (Fig.  2, bottom) . The effect of smoking status was similar for all four GUSTO-I treatment strategies.
Muhivariable analysis.
The results of the multivariate analysis are shown in Figure 3 . When considered without regard to other covariates, nonsmoking status was associated with substantially higher 30-day mortality. A portion of this smoking effect was explained by the fact that the nonsmokers were older and tended to be women. When the entire mortality model was used, current smoking status remained independently associated with lower mortality (odds ratio [OR] 1.25 for nonsmokers vs. current smokers, 95% confidence interval [CI] 1.11 to 1.39). When the angiographic substudy population was examined separately, the odds ratios were quite similar to those for the entire population, although the tests were less significant (unadjusted OR 3.36 for 30-day mortality in nonsmokers in the substudy, 95% CI 2.08 to 5.41). When age and gender were accounted for, the odds ratios continued to favor smokers, although the comparison was no longer significant (OR 1.21, 95% CI 0.71 to 2.08). The odds ratio decreased further after adjustment for all baseline clinical variables (OR 1.08, 95% CI 0.59 to 1.96) and after adjustment for differences in clinical characteristics, coronary anatomy and left ventricular dysfunction (OR 0.93, 95% CI 0.46 to 1.88).
Discussion
An increased mortality risk from coronary artery disease has long been associated with smoking (1-4). However, there is evidence (5) (6) (7) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) that smokers who are admitted to the hospital for acute myocardial infarction have a significantly better outcome than nonsmokers and, in most aspects, than patients who stopped smoking before their myocardial infarction (7). These apparently contradictory results have been explained in some studies by the poorer baseline risk profile of the nonsmoking patients (13) (14) (15) (16) . Smokers have been found to be significantly younger and to have a more favorable risk profile at admission (7, (14) (15) (16) (17) (18) (19) (20) (21) . The increased in-hospital mortality found in nonsmokers in the present study was further corroborated by the significantly higher mortality seen in current smokers as the numbers of cigarettes smoked each day decreased (p < 0.001) (Fig. 2) .
Several potential explanations have been offered for this "smoker's paradox," including the theory that a large proportion of current smokers suffer prehospital sudden deaths (22) (23) (24) . Others (25) have postulated some favorable effect that the sudden withdrawal of cigarettes may have on vascular and hematologic variables.
Different pathogenesis. Our results, obtained from analyses of >40,000 patients with acute myocardial infarction and corroborated by results of a 2,400-patient angiographic substudy, provide a partial mechanistic explanation for the "smoker's paradox." These data support the hypothesis (7) that the type of lesion that precipitates myocardial infarction in smokers is less severe and may be generated by a different mechanism.
1. Our results confirm earlier observations (16, 21, 26) that angiographically recorded coronary lesions may be less extensive in smokers. In the Coronary Artery Surgery Study (CASS) registry (26) , the extent of coronary disease (total number of segments with ->50% stenosis) was significantly less in male smokers >45 years old than in nonsmokers. In the TIMI II study, current smokers had significantly less multivessel disease than ex-smokers and nonsmokers and fewer infarctions of the left anterior descending artery. (16) . In the GUSTO-I angiographic substudy, current smokers had a significantly higher rate of single-vessel disease.
2. As in earlier reports (16, 27) , smokers in GUSTO-I had more right coronary artery infarctions (49% vs. 38%, p < 0.0001) than nonsmokers. In view of the conflicting data on the influence of infarct location on arterial patency after thrombolytic therapy (27) , it is not clear whether this lesion distribution is related to the higher patency rates observed in smokers in the present study. It may suggest that lesions in the right coronary artery are more thrombogenic, perhaps related to the phasic flow in the right coronary artery, differing from that in the left anterior descending coronary artery because of the lower systolic compressive forces in the right ventricle (28) .
3. TIMI grade 3 flow in the infarct-related artery was found at the 90-rain coronary angiography in a larger proportion of current and ex-smokers than nonsmokers (p = 0.02). In an analysis from the second Thrombolytic Trial of Eminase in Acute Myocardial Infarction (TEAM-2) (20), significantly more smokers than nonsmokers achieved complete patency (TIMI grade 3 flow). Similar to our observation, the increase in TIMI grade 3 flow in smokers was at the expense of grade 2 flow, which was relatively overrepresented in nonsmokers (20) . Current smokers also had significantly fewer angiographic reocclusions and clinical reinfarctions than nonsmokers and ex-smokers.
Recently, thrombus volume has been found to be increased twofold in blood from cigarette smokers (exposed to high shear conditions typical of moderately stenosed arteries) (29) . The similar incidence of visible thrombi in each group in our study and the lack of greater resolution at follow-up angiography in smokers do not seem to support the hypothesis that smokers have more or larger thrombi initially than patients who have never smoked. However, the significantly lower extent of atherosclerotic coronary disease, higher incidence of nonanterior wall infarctions, greater incidence of TIMI grade 3 flow at 90 min and significantly lower rate of reocclusion in smokers do lend support to a more thrombogenic etiology of myocardial infarction in these patients (7) . Thus, smoking patients with a myocardial infarction may respond better to either spontaneous or therapeutic thrombolysis.
Study limitations. Although the present clinical trial provides detailed data about a well characterized population, only a minority of patients with acute myocardial infarction are candidates for thrombolytic therapy. Patients who are not candidates are older, more often female and have a higher mortality rate. Also, we could not provide potentially valuable information for ex-smokers about the duration of time since they had stopped smoking.
Conclusions. Smokers in GUSTO-I presented an average of 11 years earlier than nonsmokers, which accounted for most of their survival advantage. They also constituted a large proportion of our patients (44%). Because smokers are more than twice as likely to have a myocardial infarction as nonsmokers (30), the resulting mortality from myocardial infarction in the general population is about twice as high in smokers as in those who have never smoked (1, 4) . However, in one study (4) former smokers had a cardiovascular mortality rate approaching that of those who had never smoked, independent of the age at which smoking stopped. These findings argue for continuing vigorous efforts to prevent people from taking up smoking and encouraging smokers to quit.
